Group 2 innate lymphoid cells are recruited to the nasal mucosa in patients with aspirin‐exacerbated respiratory disease

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Allergy and Clinical Immunology

• Publication date

  2017-07-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.jaci.2016.11.023PMID 28279492PMCID PMC5496786
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Eosinophil production of prostaglandin D2 in patients with aspirin-exacerbated respiratory disease.

  2016cited by this paper
• Type 2 innate lymphoid cells in induced sputum from children with severe asthma.

  2016cited by this paper
• Chronic Rhinosinusitis with Nasal Polyps.

  2016cited by this paper
• IL-1β, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs

  2016cited by this paper
• Thymic stromal lymphopoietin controls prostaglandin D2 generation in patients with aspirin-exacerbated respiratory disease.

  2016cited by this paper
• Group 2 innate lymphocytes (ILC2) are enriched in active eosinophilic esophagitis.

  2015cited by this paper
• Omalizumab in the treatment of aspirin-exacerbated respiratory disease.

  2015cited by this paper
• Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature.

  2015cited by this paper
• Prostaglandin D₂: a dominant mediator of aspirin-exacerbated respiratory disease.

  2015cited by this paper
• Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene–Driven IL-33–Mediated Mast Cell Activation Pathway

  2015cited by this paper
• At the Bench: Understanding group 2 innate lymphoid cells in disease

  2015cited by this paper
• Enhanced innate type 2 immune response in peripheral blood from patients with asthma.

  2014cited by this paper
• Prostaglandin D2 regulates human type 2 innate lymphoid cell chemotaxis.

  2014cited by this paper
• Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy.

  2014cited by this paper
• Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells☆

  2014cited by this paper
• Increased ILC2s in the eosinophilic nasal polyp endotype are associated with corticosteroid responsiveness.

  2014cited by this paper
• TSLP Elicits IL-33–Independent Innate Lymphoid Cell Responses to Promote Skin Inflammation

  2013cited by this paper
• Thymic stromal lymphopoietin activity is increased in nasal polyps of patients with chronic rhinosinusitis.

  2013cited by this paper
• Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production.

  2013cited by this paper
• IL-33–Responsive Lineage−CD25+CD44hi Lymphoid Cells Mediate Innate Type 2 Immunity and Allergic Inflammation in the Lungs

  2012cited by this paper
• Innate and adaptive immune responses in asthma

  2012cited by this paper
• Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity.

  2012cited by this paper
• Aspirin-intolerant asthma (AIA) assessment using the urinary biomarkers, leukotriene E4 (LTE4) and prostaglandin D2 (PGD2) metabolites.

  2012cited by this paper
• Human T(H)2 cells respond to cysteinyl leukotrienes through selective expression of cysteinyl leukotriene receptor 1.

  2012cited by this paper
• Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161

  2011cited by this paper
• Innate lymphoid cells mediate influenza-induced airway hyper-reactivity independently of adaptive immunity

  2011cited by this paper
• Mediators of inflammation in nasal lavage from aspirin intolerant patients after aspirin challenge.

  2010cited by this paper
• Use of intranasal ketorolac and modified oral aspirin challenge for desensitization of aspirin-exacerbated respiratory disease.

  2010cited by this paper
• Th9 and allergic disease

  2009cited by this paper
• Cutting Edge: The ST2 Ligand IL-33 Potently Activates and Drives Maturation of Human Mast Cells1

  2007cited by this paper
• Comparison of specific gravity and creatinine for normalizing urinary reproductive hormone concentrations.

  2004cited by this paper
• A controlled study of 9alpha,11beta-PGF2 (a prostaglandin D2 metabolite) in plasma and urine of patients with bronchial asthma and healthy controls after aspirin challenge.

  2003cited by this paper
• Cutting Edge: Agonistic Effect of Indomethacin on a Prostaglandin D2 Receptor, CRTH2

  2002cited by this paper
• Inhaled leukotriene E(4), but not leukotriene D(4), increased airway inflammatory cells in subjects with atopic asthma.

  2001cited by this paper
• Natural history of aspirin-induced asthma. AIANE Investigators. European Network on Aspirin-Induced Asthma.

  2000cited by this paper
• Montelukast is only partially effective in inhibiting aspirin responses in aspirin-sensitive asthmatics.

  2000cited by this paper
• Natural history of aspirin‐induced asthma

  2000cited by this paper
• Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma.

  1993cited by this paper
• Effect of a thromboxane receptor antagonist on PGD2- and allergen-induced bronchoconstriction.

  1989cited by this paper
• Aspirin-induced asthma: Hypersensitivity to fenoprofen and ibuprofen in relation to their inhibitory action on prostaglandin generation by different microsomal enzymic preparations

  1976cited by this paper
• Aspirin-induced asthma. Hypersensitivity to fenoprofen and ibuprofen in relation to their inhibitory action on prostaglandin generation by different microsomal enzymic preparations.

  1976cited by this paper

• Two Distinct Transcriptional Subtypes of Severe Type 2 Asthma in NSAID-Exactableerbated Respiratory Disease.

  2026cites this paper
• Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N-ERD Patients.

  2025cites this paper
• Immunological Mechanisms of Chronic Rhinosinusitis: Insights From Single-Cell Analysis

  2025cites this paper
• Effect of Aspirin Challenge on Innate Lymphoid Cells in Asthma Patients With Aspirin Hypersensitivity

  2025influential citation
• Neuromedin U Activation of Group 2 Innate Lymphocytes Exacerbates Local Inflammation of Nasal Mucosa in Allergic Rhinitis

  2025cites this paper
• Indomethacin Abolishes the Potentiation Effect of Testosterone on the Relaxation Induced by Salbutamol and Theophylline by Directly Blocking the K+ Channels in Airway Smooth Muscle

  2025cites this paper
• The immunology of asthma and chronic rhinosinusitis

  2025cites this paper
• Mast Cells in Aspirin-Exacerbated Respiratory Disease

  2024cites this paper
• Basic implications on three pathways associated with SARS-CoV-2

  2024cites this paper
• Unique effect of aspirin on local 15‐oxo‐eicosatetraenoic acid synthesis in asthma patients with aspirin hypersensitivity

  2024cites this paper
• Low Prostaglandin E2 but High Prostaglandin D2, a Paradoxical Dissociation in Arachidonic Acid Metabolism in Aspirin-Exacerbated Airway Disease: Role of Airway Epithelium

  2024cites this paper
• New insights into the mechanisms of aspirin-exacerbated respiratory disease

  2024cites this paper
• Group 2 Innate Lymphoid Cells in Allergic Rhinitis

  2024cites this paper
• Critical pathomechanisms of NSAID-exacerbated respiratory disease (N-ERD) clarified by treatment with omalizumab, an anti-IgE antibody.

  2024cites this paper
• Mucosal LTE4, PGD2 and 15(S)-HETE as potential prognostic markers for polyp recurrence in chronic rhinosinusitis.

  2024cites this paper
• Phenotype overlap in the natural history of asthma

  2023cites this paper
• Genomics of Treatable Traits in Asthma

  2023cites this paper
• GEMA 5.3. Spanish Guideline on the Management of Asthma

  2023cites this paper
• Can we apply biomarkers in the management of non-steroidal anti-inflammatory drug exacerbated respiratory disease?

  2023cites this paper
• Lower serum 15-HETE level predicts nasal ILC2 accumulation during COX-1 inhibition in AERD

  2023cites this paper
• Treatment mechanism of immune triad from the repurposing drug against COVID-19

  2023cites this paper
• Different inflammatory features of asthma according to gut microbiome enterotype

  2023cites this paper
• The Functional Role of Group 2 Innate Lymphoid Cells in Asthma

  2023cites this paper
• Non‐eosinophilic asthma in nonsteroidal anti‐inflammatory drug exacerbated respiratory disease

  2023cites this paper
• NSAID-exacerbated respiratory disease (N-ERD): a population study

  2022cites this paper
• A decreased prevalence of group 2 innate lymphoid cells in blood is associated with good postoperative outcomes in patients with chronic rhinosinusitis.

  2022cites this paper
• Bronchial epithelial cell transcriptome shows endotype heterogeneity of asthma in patients with NSAID-exacerbated respiratory disease.

  2022cites this paper
• Updates on immune mechanisms in aspirin-exacerbated respiratory disease.

  2022cites this paper
• ILCs and Allergy.

  2022cites this paper
• Role of leptin/ILC2 axis in allergic rhinitis in obese children.

  2022cites this paper
• T Cells and Group 2 Innate Lymphoid Cells 2

  2022cites this paper
• Targeting eosinophils in respiratory diseases: Biological axis, emerging therapeutics and treatment modalities.

  2021cites this paper
• Intranasal Ketorolac, Diagnosis and Desensitization for Aspirin Exacerbated Respiratory Disease.

  2021cites this paper
• Steroid-resistant human inflammatory ILC2s are marked by CD45RO and elevated in type 2 respiratory diseases

  2021cites this paper
• Innate and adaptive immunity: ILC2 and Th2 cells in upper and lower airway allergic diseases.

  2021cites this paper
• Biomarkers for predicting response to aspirin therapy in aspirin‐exacerbated respiratory disease

  2021cites this paper
• Roles of innate lymphoid cells (ILCs) in allergic diseases: The 10-year anniversary for ILC2s.

  2021cites this paper
• Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.

  2021cites this paper
• Pathomechanisms of AERD—Recent Advances

  2021cites this paper
• New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease

  2021cites this paper
• Metabolic regulation by prostaglandin E2 impairs lung group 2 innate lymphoid cell responses

  2021cites this paper
• Group 2 innate lymphoid cells in nasal polyposis.

  2020cites this paper
• Chronic Rhinosinusitis and Concomitant Medical Disorders

  2020influential citation
• Regulation of Human Innate Lymphoid Cells in the Context of Mucosal Inflammation

  2020cites this paper
• ILC2 Lung-Homing in Cystic Fibrosis Patients: Functional Involvement of CCR6 and Impact on Respiratory Failure

  2020cites this paper
• Nasal Polyposis and Aspirin-Exacerbated Respiratory Disease.

  2020cites this paper
• The Role of Mast Cells in Aspirin-Exacerbated Respiratory Disease (AERD) Pathogenesis: Implications for Future Therapeutics

  2020cites this paper
• The Biology of Prostaglandins and Their Role as a Target for Allergic Airway Disease Therapy

  2020cites this paper
• NSAID-ERD Syndrome: the New Hope from Prevention, Early Diagnosis, and New Therapeutic Targets

  2020cites this paper
• Lipid-mediated innate lymphoid cell recruitment and activation in AERD.

  2020cites this paper
• Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial

  2020cites this paper
• Aspirin-exacerbated respiratory disease.

  2020cites this paper
• Adult chronic rhinosinusitis

  2020cites this paper
• Cellular interactions in aspirin-exacerbated respiratory disease

  2020cites this paper
• Heterogeneity of lower airway inflammation in patients with NSAID-exacerbated respiratory disease.

  2020cites this paper
• Innate lymphoid cells in asthma: pathophysiological insights from murine models to human asthma phenotypes

  2019cites this paper
• Group 2 innate lymphoid cells and eosinophilic chronic rhinosinusitis

  2019cites this paper
• Prostaglandin E2 in NSAID-exacerbated respiratory disease: protection against cysteinyl leukotrienes and group 2 innate lymphoid cells

  2019cites this paper
• Urinary Markers of Mast Cell Disease and Their Role in Diagnosis and Management

  2019cites this paper
• The role of innate lymphoid cells in nasal inflammation and cancer.

  2019cites this paper
• Increased expression of type 2 innate lymphoid cells in pediatric patients with allergic rhinitis.

  2019cites this paper
• Subphenotypes of nonsteroidal antiinflammatory disease‐exacerbated respiratory disease identified by latent class analysis

  2019cites this paper
• Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps

  2019cites this paper
• Aspirin-exacerbated respiratory disease (AERD): Current understanding of AERD.

  2019cites this paper
• Sputum biomarkers during aspirin desensitization in nonsteroidal anti-inflammatory drugs exacerbated respiratory disease.

  2019cites this paper
• Group 2 Innate Lymphoid Cells in Airway Diseases.

  2019cites this paper
• Innate Lymphoid Cells in Mucosal Immunity

  2019cites this paper
• Aspirin-exacerbated Respiratory Disease: A Syndrome of Mast Cell–mediated PgD2 Overproduction

  2019cites this paper
• The Cytokines of Asthma.

  2019cites this paper
• Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-Exacerbated Respiratory Disease: A Prospective Trial.

  2019cites this paper
• Aspirin Exacerbated Respiratory Disease: Epidemiology, Pathophysiology, and Management

  2019cites this paper
• Activation of group 2 innate lymphoid cells after allergen challenge in asthmatic patients.

  2019cites this paper
• Heterogeneity of NSAID-Exacerbated Respiratory Disease: has the time come for subphenotyping?

  2019cites this paper
• Determination of potential childhood asthma biomarkers using a powerful methodology based on microextraction by packed sorbent combined with ultra-high pressure liquid chromatography. Eicosanoids as case study.

  2019cites this paper
• Role of Group 2 Innate Lymphocytes in Aspirin-exacerbated Respiratory Disease Pathogenesis

  2018cites this paper
• Airway innate lymphoid cells in the induction and regulation of allergy

  2018cites this paper
• Prostaglandin‐cytokine crosstalk in chronic inflammation

  2018cites this paper
• The group 2 innate lymphoid cell (ILC2) regulatory network and its underlying mechanisms

  2018cites this paper
• NSAIDs hypersensitivity: questions not resolved

  2018cites this paper
• Lipid regulation of group 2 innate lymphoid cell function: Moving beyond epithelial cytokines.

  2018cites this paper
• The role of basophils as innate immune regulatory cells in allergy and immunotherapy

  2018cites this paper
• Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications

  2018cites this paper
• Novel innate and adaptive lymphocytes: The new players in the pathogenesis of inflammatory upper airway diseases

  2018cites this paper
• Innate lymphoid cells and allergic disease.

  2017cites this paper
• Cytokine and Lipid Mediator Regulation of Group 2 Innate Lymphoid Cells (ILC2s) in Human Allergic Airway Disease

  2017cites this paper
• Advanced Role of Neutrophils in Common Respiratory Diseases

  2017cites this paper
• Leukotriene C4 Potentiates IL-33–Induced Group 2 Innate Lymphoid Cell Activation and Lung Inflammation

  2017cites this paper
• Cytometric Gating Stringency Impacts Studies of Type 2 Innate Lymphoid Cells in Asthma.

  2017cites this paper